Opinion

Video

Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC

Alan Chin, PharmD, BCOP, examines the PALOMA-3 trial's influence on the treatment of EGFR-mutated metastatic NSCLC and explores the evolving role of antibody-drug conjugates (ADCs) in the therapeutic landscape of EGFR-mutated NSCLC.

  1. How might the advent of subcutaneous amivantamab, currently being studied in the PALOMA-3 trial, impact the treatment of EGFR-mutated metastatic NSCLC? What opportunities or challenges might this impose?
  2. How do you see the role of antibody-drug conjugates (ADCs) evolving in the treatment landscape of EGFR-mutated NSCLC, and are there any in the pipeline that you are particularly excited about?
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
X-ray image of lung cancer -- Image credit: Sebastian Kaulitzki | stock.adobe.com
December 19th 2024

FDA Approves Ensartinib for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Gillian McGovern, Assistant Editor
Site Logo
December 20th 2024

Examining the 505(b)(2) Pathway and Implementation into EHR

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Lung cancer concept | Image Credit: © Mikki Orso - stock.adobe.com
December 5th 2024

Zenocutuzumab-zbco Granted Accelerated Approval for Patients With NSCLC, Pancreatic Ductal Adenocarcinoma

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

X-ray scans of lungs -- Image credit: Dario Lo Presti | stock.adobe.com
December 5th 2024

FDA Grants Breakthrough Therapy Designation to Sac-TMT for Previously Treated NSCLC

Gillian McGovern, Assistant Editor
patient listening to doctor - Image credit: Konstantin Yuganov | stock.adobe.com
November 27th 2024

New Strategies in SCLC and DLBCL Are Transforming the Treatment Landscape

Kennedy Ferruggia, Assistant Editor